Introduction
The kainic acid (KA, Fig. 1A ) receptors belong to the class of ionotropic glutamate receptors and are believed to mediate a modulatory excitatory response in the central nervous system. The KA receptors comprise five subunits, termed GluK1-5 and are tetrameric in structure (dimer of dimers). While the subunits GluK1-3 may form functional homomeric as well as heteromeric receptors, subunits GluK4,5 only form functional receptors with GluK1-3. To study the role and function of each of the KA receptor subtypes, it is essential that subtype selective ligands (pharmacological tools) are available. While selective GluK1 agonists and antagonists have been reported (Fig. 1B) , selective ligands for the GluK2-5 subtypes remain to be discovered. 1, 2 In order to achieve this, extensive structure-activity-studies are continuously performed, which includes binding affinity studies of synthesized compounds at homomeric, recombinant KA receptor subtypes. Readily accessible radioligands are essential to accomplish this, and previous work-intensive strategies have led to the synthesis of [ (Fig. 1C) as GluK1-selective radioligands. The high affinity KA receptor ligand SYM2081 (Fig. 1C ) has also been employed as the radioligand in binding assays of homomeric GluK1-3 receptors, 5 however its difficult purification makes it less attractive to produce and it is no longer commercially available. While commercially available 
Results and discussion

Synthesis
Firstly, we pursued a direct bromination of commercially available UBP310 to obtain the dibromothiophene precursor previously reported for the synthesis of [ 3 H]-UBP310 (Scheme S1, ESI ‡). 3 However, bromination took place at the uracil ring only, and all attempts failed to following incorporate deuterium (see ESI ‡ for details).
We next turned to investigate the high affinity, selective GluK1 ligand NF608 (Fig. 1 ) which also comprises a thiophene ring. Its synthesis is described in only two steps from commercially available thienoĳ3,2-d]pyrimidine-2,4Ĳ1H,3H)-the thiophene ring of 3 under standard conditions (Br 2 in AcOH or TFA, rt to 90°C) (Scheme 1). However, none of the corresponding bromo or dibromo derivatives comprised by general structure 4 were observed but only the expected cleavage of the BOC group.
We therefore revised the strategy to introduce the bromine functionality earlier in the synthesis (Scheme 1), and indeed we were able to brominate the thiophene ring of 1 in the 7 position to give 5. Disappointingly, alkylation at N 1 with lactone 2 (ref. 12) as the electrophile was unproductive (NaH, DMF, −65 to 80°C) presumably due to the bulkiness of the bromine atom (Scheme 1). For that reason, we turned to pursue bromination of the 6 position of the thienopyrimidine ring in order to allow for following alkylation at N 1 .
The synthesis of key bromo intermediate 13 (Scheme 2) commenced with N-protection of commercially available methyl 3-aminothiophene-2-carboxylate (7) with trichloroacetyl isocyanate in THF to afford compound 8 in 93% yields. 13 Subsequent bromination with Br 2 in acetic acid at 80°C successfully provided exclusively 5-bromo-thiophene 9, which was then treated with 2 M ammonia in methanol to afford urea 10. 13 Cyclization with potassium tert-butoxide in DMF, furnished the desired heterocyclic product 11. 13 Alkylation at N 1 with lactone 2 12 was performed using sodium hydride as base in DMF, as described in a similar procedure. 7 The alkylation product 12 was obtained in only 18% -a yield which could likely be optimized. Cleavage of the BOC group in the presence of 2 M aq HCl provided key bromo amino acid intermediate 13, in overall 6 steps. Deuteration over Pd/C in a basic aqueous media gave 80% deuterium incorporation, furnishing deuterated product [D6]-NF608 together with NF608, in overall 57% yield.
Tritiation
Having established the method for deuterium incorporation, tritiation was carried out by use of T 2 (gas) with Pd/C as cata- 
GluK1 binding pharmacology
Assay validation
Based upon our previous publication we anticipated [ 3 H]-NF608 to be a high affinity radioligand at GluK1 since unlabeled NF608 had shown a K i of 5.3 nM. 7 Initial tests indicated high level of specific binding of the radiolabel to homomeric rat GluK1 expressed in sf9 cell membranes and subsequently an assay validation was conducted using 1 mM (S)-glutamate to define nonspecific binding. No specific binding was seen using uninfected sf9 cell membranes. A series of buffers, temperatures, pH conditions and washing protocols were evaluated (Table 1 ) and 50 mM Tris-HCl pH 7.1 at 4°C with 2 × 4 mL filter washes was found to be optimal for specific binding to GluK1. There was no pH dependency of the binding between pH 7.1 and 7.8. Binding of [ 3 H]-NF608 to native GluK1 in rat brain P2 membranes was tested using the high affinity GluK1-selective ligand 10 μM UBP310 to evaluate nonspecific binding and, although a small amount of specific binding was detected, it was insufficient to perform pharmacological analyses at native GluK1. This is likely due to the low specific activity of the radioligand (16.3 Ci mmol −1 ).
Kinetics
The association and dissociation kinetics of [ 3 H]-NF608 binding were examined at GluK1 at 4°C (Fig. 3) . The association nM, which agrees well with the previously determined affinity of NF608 at GluK1 (K i = 5.29 ± 0.66 nM). 
Conclusion
In conclusion we have reported a short and efficient method for the radiosynthesis of the selective GluK1 radioligand 
Experimental section
Chemistry
All reactions involving dry solvents or sensitive agents were performed under a nitrogen or argon atmosphere, and glassware was dried prior to use. Commercially available chemicals were used without further purification. Solvents were dried prior to use with an SG water solvent purification system or dried by standard methods. min), were performed depending on the polarity of the compounds. For data collection and data handling, MassLynx software was used. Compounds were dried under high vacuum or freeze dried using a ScanVac Cool Safe Freeze Drier. The purity of compounds submitted for pharmacological characterization was determined by 1 H-NMR and HPLC to be >95%. Filter washing (mL)
For the tritiation experiments
Overview of the various assay conditions tested. The pH, temperature and washing conditions were only evaluated using 50 mM Tris-HCl buffer. Micromass Q-TOF Micro mass spectrometer or on a Thermo Fisher Scientific LTQ Orbitrap XLc. The tritiation reaction was performed on a custom-designed tritium manifold system manufactured by RC Tritec AG, Switzerland. Activities were measured on a Perkin-Elmer TriCarb 2900TR liquid scintillation counter (LSC) in a Zinsser Quicksafe A cocktail.
The HPLC was performed on a system consisting of a WA-TERS Delta 600 Pump and Controller, a WATERS 2487 UV detector and a RAMONA radio chromatographic detector from Raytest (Germany) with interchangeable fluid cells. For the preparative runs, the cell with a single small crystal of solid scintillator was used; for analytical runs, the column effluent was mixed with a Zinsser Quickszint Flow 302 cocktail at the ratio of 1 : 3.
tert-Butyl (S)-(2-oxooxetan-3-yl)carbamate (2).
To an icecooled solution of triphenylphosphine (95%, 7.3 g, 26.53 mmol) in anhydrous THF (50 mL), was added diethyl azidodicarboxylate (DEAD, 97%, 4.6 mL, 28.95 mmol). The resulting solution was stirred at 0°C for 15 minutes and a solution of N-(tert-butoxycarbonyl)-L-serine (99%, 5 g, 24.12 mmol) in anhydrous THF (36 mL) was added dropwise. The reaction mixture was stirred and allowed to reach room temperature overnight. Next day, the mixture was quenched with water (80 mL) and then it was diluted with EtOAc (40 mL). The aqueous layer was extracted with EtOAc (3 × 80 mL) and the collected organic layers were washed with brine (80 mL), dried over MgSO 4 and filtered. After that, the solvent of the filtrate was removed under reduced pressure to give a residue that was purified by flash chromatography (silica gel, heptaneEtOAc 95 : 5 to 7 : 3, gradient) to afford the lactone 2 as a white solid (1.7 g, 37%). 88 mmol) in anhydrous DMF (40 mL) was cooled to 0°C and then sodium hydride (60% w/w in mineral oil, 214 mg, 5.34 mmol) was added. The resulting suspension was stirred 50 minutes at room temperature. After that time, the reaction mixture was cooled again to 0°C and a solution of tert-butyl (S)-(2-oxooxetan-3-yl)carbamate (2) (1 g, 5.34 mmol) in anhydrous DMF (20 mL) was added. The resulting mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched by adding water dropwise until no reaction was observed. The solvent of the reaction mixture was co-evaporated with toluene (3 × 20 mL) to get a white solid that was divided in 6 portions and each one was dissolved in DMSO-MeCN (15 : 1, 1 mL) and purified by 6 consecutive preparative HPLC purifications (Rt: 19.53 min; flow: 10 mL min 
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Methyl 3-(3-(2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (8); methyl 5-bromo-3-(3-(2,2,2-trichloroacetyl)-ureido)thiophene-2-carboxylate (9) . Methyl 3-(3-(2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (8); methyl 5-bromo-3-(3-(2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (9) were synthesized according to ref. 13 .
Methyl 5-bromo-3-ureidothiophene-2-carboxylate (10) . To an ice-cooled suspension of 9 (7.84 g, 17.55 mmol) in anhydrous MeOH (70 mL), was added 2 M NH 3 solution (in MeOH, 17.5 mL, 35.09 mmol) and this mixture was stirred at room temperature for 30 minutes, during which time a white solid precipitated. After this period, the white solid was filtered and washed with cold MeOH (3 × 10 mL) to give the compound 10 (4.37 g, 89%) as a white solid with a purity of 98% (determined by 1 H-NMR (12) . A solution of 6-bromothienoĳ3,2-d]pyrimidine-2,4Ĳ1H,3H)-dione (11) (581 mg, 2.35 mmol) in anhydrous DMF (11.4 mL) was cooled to 0°C and then sodium hydride (60% w/w in mineral oil, 85 mg, 2.14 mmol) was added. The resulting suspension was stirred 40 minutes at room temperature. After that time, the reaction mixture was cooled again to 0°C and a solution of tert-butyl (S)-(2-oxooxetan-3-yl)carbamate (2) (400 mg, 2.14 mmol) in anhydrous DMF (10 mL) was added. The resulting mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched by adding water dropwise until no reaction was observed. The solvent of the reaction mixture was co-evaporated with toluene (3 × 10 mL) to get a white solid that was divided into 7 portions and each one was dissolved in DMSO-MeCN (15 : 1, 1.5 mL) and purified by 7 consecutive preparative HPLC purifications (Rt: 28.60 min; flow: 10 mL min found, 333.9.
A suspension of (S)-3-(6-Bromo-2,4-dioxo-3,4-d i h y d r o t h i e n o ĳ 3 , 2 -d ] p y r i m i d i n -1 Ĳ 2 H ) -y l ) -2 -( ( t e r tbutoxycarbonyl)amino)propanoic acid (12) (122 mg, 0.28 mmol) in 2 M aq HCl (6 mL), was heated to 50°C during 1 hour. After that time, the solvent and volatiles were removed under reduced pressure to afford the title compound as a white solid (98 mg, 94%), which was used in next reaction step without further purification. 1 
. Pd/C (1.8 mg, 10% Pd on activated C, waterwet) was weighed in a small flask that was repeatedly filled and evacuated with N 2 (3 times), and then D 2 (3 times). In parallel, (S)-2-(6-bromo-2,4-dioxo-3,4-dihydrothienoĳ3,2-d]-pyrimidin-1Ĳ2H)-yl)-1-carboxyethan-1-aminium chloride (13) (9 mg, 0.024 mmol) was weighed in a separate flask that was repeatedly filled and evacuated with N 2 (3 times). Then, water (240 μL) and 1 M aq NaOH (69 μL, 0.069 mmol) were added to afford a suspension that was heated to 60°C for 5 minutes until getting a clear solution that was transferred to the previous flask with Pd/C. The resulting mixture was repeatedly filled and evacuated with D 2 (3 times), and stirred vigorously at room temperature overnight under D 2 (1 atm). After this period, the reaction mixture was filtered through a plug of Celite®, and the filtrand was washed with water (3 × 3 mL). Then, the filtrate was concentrated in vacuo to give the deuterated : hydrogenated disodium salts of products [D6]-NF608 : NF608 in a 4 : 1 ratio, as a white solid (4 mg, 57%, 80% D-incorporation). with Pd/C [30%] (2.6 mg, 2 w/w eq.) in H 2 O (1 mL) and NaOH (20 μL, 1 M) in round reaction flask (2 mL) equipped with a Teflon-coated stir bar was mounted onto tritium manifold system. The reaction mixture was degassed three times in a repeated freeze-thaw cycle (liquid nitrogen), and pressure of released tritium gas was adjusted to 515 mbar (6.9 Ci). The reaction mixture was vigorously stirred for 3 hours. The reaction mixture was frozen with liquid nitrogen and unreacted tritium gas was reabsorbed in the uranium bad. The reaction mixture was heated up to room temperature and the catalyst was filtered off with a PTFE syringe filter (0.45 μm). The tritiation flask and filter
